Selected Publications

Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M.: Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia Jul 2025.

Lai CE, Leahy TP, Turner AJ, Thomassen A, Wang L, Sheppard AD, Cortes J: Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm. Leuk Lymphoma Jun 2025.

Catherin Lai: Navigating Practice Barriers to Mutation Testing in AML. Kaplan, virtual June 2025 Notes: Interview/podcast recording.

Catherine Lai: Charting the Course of ALL: From Diagnosis to Advances. Leukemia & Lymphoma Society, LLS Podcast series for Professionals "Treating Blood Cancers" June 2025 Notes: Podcast.

Carraway HE, Brunner AM, Lai CE, Luskin MR, Park J, Perl AE, Stein EM, Wang ES, Zeidan AM, Zeidner JF, Komrokji R: Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Clin Lymphoma Myeloma Leuk Mar 2025.

Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv Feb 2025.

Ashley D. Hadjis, Honghong Sun, Yangzhu Du, Rebecca T. Brown, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Shannon R. McCurdy: Graft-Versus-Host Disease (GVHD) and Senescence-Associated Biomarkers Correlate with Frailty and Survival in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT). Transplantation and Cellular Therapy Feb 2025.

Meghann Cody, Dr. Heather E. Stefanski, Jason Oakes, Sam Sharf, Ruth Bakken, Anna M. DeSalvo, John P. Miller, Steven M. Devine, Lucy A. Godley, Catherine E. Lai, Lacey Williams: Implementation and Early Insights of NMDP's New Post-Transplant Genetic Findings Management Process. Transplantation and Cellular Therapy Feb 2025.

Shannon R. McCurdy, Anthony D Sung, Rebecca T. Brown, Marni Kessler, Nelson J. Chao, Thuy T. Koll, Alfred Fisher, Ernaya Johnson, Meagan Lew, Lauren Bohannon, Sanghee Hong, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Daria Babushock, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Vijaya Raj Bhatt, Phyllis Gimotty: Machine Learning Models Demonstrate Gait Speed As the Best Predictor of Survival and Relapse-Free Survival in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy Feb 2025.

Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 2025.